Esophageal Neoplasms
Conditions
Brief summary
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.
Interventions
DRUGan anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
This is an observational study
Sponsors
The First Affiliated Hospital of Zhengzhou University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Esophageal cancer confirmed by histopathology or cytology 2. Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy 3. Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers 4. Patients who sign informed consent and voluntarily join the study
Exclusion criteria
1. Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study 2. Patients who are undergoing treatment regimen of blind trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | Progression Free Survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | From date of admission until the date of death from any cause, assessed up to 24 months | Overall Survival |
Countries
China
Outcome results
None listed